Alphamab Oncology (HKG:9966)

Alphamab Oncology Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	825.57	1,112	1,086	1,069	803.31	185.32
Short-Term Investments	819.23	459.35	321.25	247.86	1,128	1,835
Trading Asset Securities	-	-	-	33.33	54.01	43.53
Cash & Short-Term Investments	1,645	1,571	1,407	1,350	1,985	2,064
Cash Growth	12.92%	11.67%	4.21%	-31.99%	-3.82%	-13.36%
Accounts Receivable	52.98	20.3	7.13	15.49	7.61	-
Other Receivables	55.31	37.77	65.42	64.03	59.92	84.8
Receivables	108.29	58.07	72.55	79.52	67.53	84.8
Inventory	82.08	81.81	78.75	64.64	57.91	44.32
Other Current Assets	-	-	-	-	5.63	5.86
Total Current Assets	1,835	1,711	1,559	1,495	2,117	2,199
Property, Plant & Equipment	520.8	524.01	576.95	619.74	530.52	393.02
Other Long-Term Assets	2.97	6.4	1.63	3.26	58.02	47.27
Total Assets	2,359	2,242	2,137	2,118	2,705	2,640
Accounts Payable	53.25	42.29	31.54	17.63	28.48	5.28
Accrued Expenses	118	118.93	119.89	135.36	109.04	77.61
Current Portion of Long-Term Debt	157.75	52.26	75	175	449.99	188
Current Portion of Leases	1.68	2.44	5.5	15.11	13.82	10.15
Current Unearned Revenue	16.68	15.48	6.86	13.07	6.38	5.69
Other Current Liabilities	21.34	22.64	28.05	28.74	29.55	42.82
Total Current Liabilities	368.7	254.04	266.84	384.91	637.26	329.54
Long-Term Debt	113.18	129.98	175	150	153.83	21.35
Long-Term Leases	0.87	1.27	1.58	5.28	19.63	3.31
Long-Term Unearned Revenue	21.2	24.57	21.58	19.67	24.09	12.24
Total Liabilities	503.95	409.87	465	559.86	834.8	366.44
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	-	4,055	4,053	3,726	3,717	3,713
Retained Earnings	-	-2,177	-2,343	-2,132	-1,807	-1,394
Treasury Stock	-9.19	-9.19	-	-	-	-
Comprehensive Income & Other	1,864	-37.43	-37.64	-35.85	-39.84	-45.45
Total Common Equity	1,855	1,832	1,672	1,558	1,870	2,273
Shareholders' Equity	1,855	1,832	1,672	1,558	1,870	2,273
Total Liabilities & Equity	2,359	2,242	2,137	2,118	2,705	2,640
Total Debt	273.48	185.96	257.08	345.39	637.27	222.81
Net Cash (Debt)	1,371	1,386	1,150	1,005	1,348	1,841
Net Cash Growth	21.36%	20.46%	14.45%	-25.46%	-26.78%	-13.52%
Net Cash Per Share	1.38	1.41	1.20	1.07	1.44	1.98
Filing Date Shares Outstanding	960.18	961.97	964.84	939.72	934.94	934.94
Total Common Shares Outstanding	960.18	961.97	964.84	939.72	934.94	934.94
Working Capital	1,466	1,457	1,292	1,110	1,479	1,870
Book Value Per Share	1.93	1.90	1.73	1.66	2.00	2.43
Tangible Book Value	1,855	1,832	1,672	1,558	1,870	2,273
Tangible Book Value Per Share	1.93	1.90	1.73	1.66	2.00	2.43
Buildings	-	298.2	303.51	285.28	227.4	237.74
Machinery	-	397.62	384.82	286.3	152.46	120.65
Construction In Progress	-	7.41	0.89	90.83	143.08	23.42
Leasehold Improvements	-	6.26	6.26	6.75	1.9	0.41

Source: S&P Global Market Intelligence. Standard template. Financial Sources.